Cargando…

Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer’s Disease in Relation to Therapeutic Editing Tools

Alzheimer’s disease (AD) is biologically defined as a complex neurodegenerative condition with a multilayered nature that leads to a progressive decline in cognitive function and irreversible neuronal loss. It is one of the primary diseases among elderly individuals. With an increasing incidence and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stanciu, Gabriela Dumitrita, Ababei, Daniela Carmen, Rusu, Razvan Nicolae, Bild, Veronica, Tamba, Bogdan-Ionel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228826/ https://www.ncbi.nlm.nih.gov/pubmed/35745842 http://dx.doi.org/10.3390/pharmaceutics14061270

Ejemplares similares

Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2021)

Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2020)

Renal Contributions in the Pathophysiology and Neuropathological Substrates Shared by Chronic Kidney Disease and Alzheimer’s Disease
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2020)

Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2019)

Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases
por: Bild, Walther, et al.
Publicado: (2022)

Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia
por: Ababei, Daniela-Carmen, et al.
Publicado: (2023)

Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
por: Vasincu, Alexandru, et al.
Publicado: (2022)

Self-Medication in Rural Northeastern Romania: Patients’ Attitudes and Habits
por: Rusu, Razvan-Nicolae, et al.
Publicado: (2022)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2023)

Relevance of Surface Neuronal Protein Autoantibodies as Biomarkers in Seizure-Associated Disorders
por: Stanciu, Gabriela Dumitrita, et al.
Publicado: (2019)

Secondary Metabolites from Plants Possessing Inhibitory Properties against Beta-Amyloid Aggregation as Revealed by Thioflavin-T Assay and Correlations with Investigations on Transgenic Mouse Models of Alzheimer’s Disease
por: Stefanescu, Raluca, et al.
Publicado: (2020)

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?
por: Filipiuc, Leontina Elena, et al.
Publicado: (2021)

The Impact of Some Modulators of the Renin–Angiotensin System on the Scopolamine-Induced Memory Loss Mice Model
por: Ababei, Daniela-Carmen, et al.
Publicado: (2023)

Contributions of Mass Spectrometry to the Identification of Low Molecular Weight Molecules Able to Reduce the Toxicity of Amyloid-β Peptide to Cell Cultures and Transgenic Mouse Models of Alzheimer’s Disease
por: Ştefănescu, Raluca, et al.
Publicado: (2019)

From Evidence to Clinical Guidelines in Antibiotic Treatment in Acute Otitis Media in Children
por: Spoială, Elena Lia, et al.
Publicado: (2021)

The A673T mutation in the amyloid precursor protein reduces the production of β-amyloid protein from its β-carboxyl terminal fragment in cells
por: Kokawa, Asuka, et al.
Publicado: (2015)

Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity
por: Vasincu, Alexandru, et al.
Publicado: (2023)

A Nanostructured Protein Filtration Device for Possible Use in the Treatment of Alzheimer’s Disease—Concept and Feasibility after In Vivo Tests
por: Schreiner, Thomas Gabriel, et al.
Publicado: (2023)

Amyloid Precursor Protein and Alzheimer’s Disease
por: Orobets, Kseniia S., et al.
Publicado: (2023)

Effects of DDT on Amyloid Precursor Protein Levels and Amyloid Beta Pathology: Mechanistic Links to Alzheimer’s Disease Risk
por: Eid, Aseel, et al.
Publicado: (2022)

Copper binding to the Alzheimer’s disease amyloid precursor protein
por: Kong, Geoffrey K.-W., et al.
Publicado: (2007)

The protective mutation A673T in amyloid precursor protein gene decreases Aβ peptides production for 14 forms of Familial Alzheimer’s Disease in SH-SY5Y cells
por: Guyon, Antoine, et al.
Publicado: (2020)

The amyloid precursor protein: beyond amyloid
por: Zheng, Hui, et al.
Publicado: (2006)

Intracerebroventricular Coadministration of Protoxin-II and Trace Elements in Rats Enhances the Analgesic Effect of the 1.7 Voltage-Gate Sodium Channel Blocker
por: Stanciu, Gabriela-Dumitrita, et al.
Publicado: (2019)

Observation of Intact and Proteolytically Cleaved Amyloid-Beta (1–40)-Oleuropein Noncovalent Complex at Neutral pH by Mass Spectrometry
por: Caba, Ioana Cezara, et al.
Publicado: (2021)

Targeting apolipoprotein E and N-terminal amyloid β-protein precursor interaction improves cognition and reduces amyloid pathology in Alzheimer’s mice
por: Sawmiller, Darrell, et al.
Publicado: (2023)

Amyloid precursor protein and amyloid precursor-like protein 2 in cancer
por: Pandey, Poomy, et al.
Publicado: (2016)

Heterogeneous Association of Alzheimer’s Disease-Linked Amyloid-β and Amyloid-β Protein Precursor with Synapses
por: Willén, Katarina, et al.
Publicado: (2017)

Interactions between amyloid, amyloid precursor protein, and mitochondria
por: Wilkins, Heather M.
Publicado: (2023)

Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy
por: Tamba, Bogdan Ionel, et al.
Publicado: (2020)

Medicinal Plants of the Family Lamiaceae in Pain Therapy: A Review
por: Uritu, Cristina M., et al.
Publicado: (2018)

The Link Between Inflammaging and Degenerative Joint Diseases
por: Rezuș, Elena, et al.
Publicado: (2019)

Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer’s disease
por: Boix, Claudia P., et al.
Publicado: (2020)

TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease
por: Hicks, David A.
Publicado: (2020)

Amyloid Precursor Protein (APP) Mediated Regulation of Ganglioside Homeostasis Linking Alzheimer's Disease Pathology with Ganglioside Metabolism
por: Grimm, Marcus O. W., et al.
Publicado: (2012)

The Amyloid Precursor Protein Intracellular Domain-Fe65 Multiprotein Complexes: A Challenge to the Amyloid Hypothesis for Alzheimer's Disease?
por: Bórquez, Daniel A., et al.
Publicado: (2012)

Baicalein reduces β-amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer’s disease transgenic mouse model
por: Zhang, She-Qing, et al.
Publicado: (2013)

Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease
por: Kirouac, Lisa, et al.
Publicado: (2017)

Insertion of the protective APP A673T mutation by CRISPR/Cas9 base editing or PRIME editing.
por: Tremblay, Jacques, et al.
Publicado: (2021)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_in5danee5po847mg1a7lnouj7q